ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Feb 03, 2023 14:00 JST
Source:
Novotech Health Holdings Pte Ltd
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
SYDNEY, AU, Feb 03, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award, said the number of cell & gene therapy trials in the region was growing 50% faster than ROW. The majority of trials are in oncology, specifically for blood cancers, viral infections, and solid tumors.
Novotech, which has extensive experience in cell & gene therapy clinical trials, is sponsoring the 6th Annual Cell And Gene Therapy Innovation Summit in Berlin, Germany (15-16 February 2023).
The company recently acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program in Europe and the US.
The acquisition means biotech clients can access Novotech's unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
The latest data shows Asia Pacific is the fastest-growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies, with China leading in the region.
The region already accounts for over a third of cell & gene therapy trial activity and shows a nearly 50% faster growth rate in cell & gene therapy trials compared to ROW between 2016 and 2021. China shows a 15% faster growth rate than the ROW. After oncology, the majority of cell & gene trials are in infectious diseases, CNS, and cardiovascular diseases.
In addition, the Asia Pacific is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022.
Novotech CEO Dr. John Moller said: "Cell & gene therapy research typically presents another level of complexity and regulatory processes which means an experienced CRO partner is vital. Our deep experience, exceptional site and investigator relationships - which also translates to patent access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the service biotechs need in this specialist sector for success."
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, selected for the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.
Download our latest data report:
Evolution of Clinical Trials in the Asia Pacific Region Compared to the US and the EU5
https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5
About Novotech (Novotech-CRO.com)
Novotech is internationally recognized as the leading Asia Pacific centred biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 2,700 staff working across offices in 20 geographies. For more information visit
https://novotech-cro.com/contact
Media Contact:
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
ASIA : +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
GC Collaborates with MHI to explore the utilization of hydrogen, ammonia and CCS technology to develop a large-scale petrochemical plant to achieve Net Zero
Dec 01, 2023 17:22 JST
NEC named among IAM's 2023 Asia IP Elite
Dec 01, 2023 14:50 JST
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Nov 30, 2023 16:25 JST
Boosting Growth Investment to Power Mobility Company Transformation Toyota-DENSO Capital Ties Revised
Nov 30, 2023 16:17 JST
Olympus's Net-Zero Targets Approved by SBTi
Nov 30, 2023 11:00 JST
Fujitsu and Macquarie University establish new research lab to accelerate development of human sensing and generative AI technologies
Nov 30, 2023 09:34 JST
NEC X and Entrepreneurs Roundtable Accelerator (ERA) Forge Strategic Partnership to Advance East Coast-based Startups
Nov 29, 2023 18:37 JST
MHI Selected as Core Company for New Research Reactor for JAEA
Nov 29, 2023 18:22 JST
Toyota: Sales, Production, and Export Results for October 2023
Nov 29, 2023 16:17 JST
Toyota Re-introduces the Land Cruiser "70" in Japan
Nov 29, 2023 13:30 JST
Mitsubishi Shipbuilding Holds Christening and Handover Ceremony in Shimonoseki for Demonstration Test Ship for Liquefied CO2 Transport
Nov 28, 2023 17:47 JST
Hitachi awarded Sustainable Markets Initiative 2023 Terra Carta Seal
Nov 28, 2023 17:43 JST
MHI Succeeded Combustion Test of Ammonia Single-Fuel Burners
Nov 28, 2023 16:40 JST
JCB partners with FrenchSys to boost card acceptance across France
Nov 28, 2023 12:00 JST
Toyota Launches IMV 0 in Thailand Providing Mobility to Make People's Lives Better through Customizability
Nov 27, 2023 17:30 JST
MHI and Orica Announce Collaboration to Explore Emissions Reduction Opportunities
Nov 27, 2023 15:29 JST
Mitsubishi Motors to Launch the New Minicab EV Electric Commercial Vehicle in Japan in December
Nov 24, 2023 16:32 JST
DOCOMO to Showcase Diverse Technologies at docomo Open House '24
Nov 22, 2023 20:39 JST
Renewal of O&M Services Contract for APM System at Dubai International Terminal 3
Nov 22, 2023 20:21 JST
Hitachi Energy unveils new emission-free alternative to diesel- powered generators
Nov 22, 2023 20:05 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval
October 17 2022 11:00 JST
More Press release >>